The election of real estate mogul Donald Trump to the presidency of the U.S. may or may not have upended the Washington establishment, but the policy implications of the election for the life sciences are as yet unknown. John Manthei of Latham & Watkins said on a Nov. 9 conference call that one important issue to device makers, the lag time between device approval and Medicare coverage known as the Valley of Death, may be tackled in legislation used to reauthorize the user fee programs. Read More
